Comparative pharmacoeconomic analysis of metastatic colorectal cancer treatment

Every year, the pharmacological market offers new medicines to increase the survival rate and improve the quality of life of patients with cancer. However, while significantly exceeding the cost of existing methods of pharmacotherapy, new technologies often lead to only a small increased efficiency. Budget resources of health care dictate the need for a rational choice of pharmacotherapeutic options for malignant neoplasms that meet the principles of ensuring maximum results and accessibility for the entire population. An important role in solving this problem is played by such a direction of pharmacoeconomic analysis as the “cost-effectiveness” method. Colorectal cancer is one of the three oncological diseases that cause the greatest socio-economic burden for the state, which is associated with the highest costs of the Russian Federation health care system. Concurrently, in the last decade, a much more favorable prognosis has been identified for patients with metastatic colorectal cancer due to the development of effective approaches to antitumor pharmacotherapy. Conducting a pharmacoeconomic review that takes into account both clinical and economic indicators when using classic chemotherapy regimens and new targeted drugs will determine the effectiveness of finances that are spent to combat this malignancy. Additionally, the need to further individualize the therapy of patients suffering from metastatic colorectal cancer and lower prices for modern antitumor drugs is undeniable.